Back to Kansas

HB2694 • 2026

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Last action
2026-04-10
Official status
Died in Committee
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

What This Bill Does

  • Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-04-10 House

    Died in Committee

  2. 2026-02-04 House

    Referred to House Committee on Health and Human Services

  3. 2026-02-04 House

    Introduced

Official Summary Text

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Current Bill Text

Read the full stored bill text
Session of 2026
HOUSE BILL No. 2694
By Representative Simmons
2-4
AN ACT concerning health and healthcare; relating to prescription
medication; enacting the opioid patients right to know act; requiring
that a healthcare provider disclose the risks of prescribed opioid use.
Be it enacted by the Legislature of the State of Kansas:
Section 1. (a) This act shall be known and may be cited as the opioid
patients right to know act.
(b) Before issuing an initial prescription of a schedule II controlled
substance pursuant to K.S.A. 65-4107, and amendments thereto, or any
other opioid pain reliever that is a prescription drug in the course of
treatment for acute or chronic pain, a prescriber shall discuss with the
patient, or the patient's parent if such patient is a minor, the risks
associated with the drugs being prescribed.
(c) The topics that the prescriber shall discuss shall include, but not
be limited to:
(1) The risk of addiction and overdose associated with opioid drugs;
(2) the dangers of taking opioid drugs with alcohol, benzodiazepines
and other central nervous system depressants;
(3) the reason that the prescription is necessary;
(4) alternative treatment that may be available; and
(5) the risks associated with the use of the drugs prescribed.
(d) The prescriber shall include a note in the patient's medical record
that such prescriber has discussed with such patient or such patient's parent
the risks of developing a physical or psychological dependence on the
schedule II controlled substance or other opioid to be prescribed and that
alternative treatment may be available.
(e) This section shall not apply to a prescription for a patient who is
currently in treatment for cancer, receiving hospice care from a licensed
hospice or palliative care or a resident of a long-term healthcare facility or
to any medications that are being prescribed for use of substance abuse or
opioid dependence.
Sec. 2. This act shall take effect and be in force from and after its
publication in the statute book.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33